“In an era where the costs to develop a drug are greater than $1 billion, and only an estimated one in 5,000 compounds ever make it to market, the benefits of conducting clinical trials in Russia are too great to ignore.
San Francisco, CA (PRWEB) March 17, 2011
ClinStar, LLC, an established CRO providing clinical research services in Russia and Eastern Europe to the pharmaceutical, biotechnology and medical device industry, announced today that NPR Marketplace aired coverage on March 9th of an interview with ClinStar President and CEO David Passov about the benefits of conducting clinical trials in Russia.
In an interview with Mr. Passov and ClinStar Senior Project Manager Dr. Tatiana Balashova, NPR Marketplace Health Desk Reporter Gregory Warner uncovers the truths about clinical trials in Russia; namely, the ability for biopharmaceutical companies to enroll patients 3 to 20 times faster than in the more established regions of North America and Western Europe.
Referring to the NPR interview, Mr. Passov says, “The clinical trial industry has been well established in North America and Western Europe for the last 25 years or so now. For many who are not familiar with clinical trials and the drug development process, Russia is considered to be an emerging region for clinical trial conduct. By most definitions, however, Russia is not an emerging country for clinical trials but rather a well established country for conducting clinical research.”
“In an era where the costs to develop a drug are greater than $1 billion, and only an estimated 1 in 5,000 compounds ever make it to market, the benefits of conducting clinical trials in Russia are too great to ignore,” says Executive Director Business Development and Marketing Erin King. “By speeding up the patient enrollment process, biopharmaceutical companies are able to shrink the clinical trial timeline and reduce the overall costs to get a drug approved,” says Ms. King.
With these kind of savings, it should come as no surprise that Mr. Warner reports the clinical trial industry in Russia is growing by 15%. But it’s not only the biopharmaceutical industry that is benefiting. More clinical trials in Russia also translates into more affordable prescription drugs in western nations and provides Russian citizens with immediate access to better healthcare as well as the opportunity to participate in a cause that will ultimately bring better healthcare to their nation in the form of more marketed drugs.
About ClinStar, LLC
ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics, with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus, with total staff of over 300 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at http://www.clinstar.com.